Intratio
Loading...
Skip to main content
Model output · Signal date 2026-10-16

Collplant Biotechnologies Ltd (CLGN) Stock Forecast Oct. 16, 2026

Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq

Follow Unlock full AI forecasts
Rating · 90D Neutral Alpha
90-day forecast Sign up free to reveal
30-day forecast Alpha
Rank in coverage Middle 30% of 5172 stocks scored
Rank correlation · 90D -14.0% Spearman, 357 dates
Market Cap $7M small-cap · #23 of 27 peers
Summary

Collplant Biotechnologies Ltd (CLGN) stock forecast summary

On Oct. 16, 2026, CLGN is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5172 stocks scored that day.

Collplant Biotechnologies Ltd is a small-cap company with a market capitalization of $7M. It ranks number 23 by market capitalization among the 27 Orthopedic, Prosthetic & Surgical Appliances & Supplies issuers in our coverage with a current forecast.

For CLGN, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -14.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -17.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)

A free account shows the exact forecast, rating and rank of 3 tickers you follow, CLGN included.

Follow CLGN free
Price

CLGN price chart and AI forecast

CLGN
Cross-section · 2026-10-16

How CLGN ranks among 5172 stocks

90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).

Fundamentals · 2025-12-31

Collplant Biotechnologies Ltd (CLGN) fundamentals

Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Orthopedic, Prosthetic & Surgical Appliances & Supplies peers listed below that report each metric.

Valuation & Market

MetricCLGNIndustry medianRank
Market Cap $7M $76M 23/27
P/B Ratio 1.13x 2.28x 15/22
EPS $-2.39 – –
Book Value/Share $3.22 – –
Revenue/Share $1.53 – –

Profitability & Margins

MetricCLGNIndustry medianRank
Gross Margin 14.8% 50.2% 18/20
Operating Margin -995.6% -8.7% 19/21
EBT Margin -995.6% -19.3% 19/21

Financial Health

MetricCLGNIndustry medianRank
Current Ratio 2.53x 2.57x 14/25
Quick Ratio 2.31x 1.89x 8/22
D/E Ratio 0.77x 0.71x 12/24
Financial Leverage 1.77x 1.71x 12/24
Working Capital $4M $51M 20/25

Cash Flow

MetricCLGNIndustry medianRank
Operating Cash Flow -$24M -$690K 22/25

Operational Efficiency

MetricCLGNIndustry medianRank
Asset Turnover 0.27x 0.72x 16/18
Receivables Turnover 2886.0x 5.6x 1/17
Inventory Turnover 4.3x 2.1x 6/22
Fixed Assets Turnover 2.0x 5.5x 17/19
Days Sales Outstanding 0 days 65 days 17/17
Days Inventory 85 days 171 days 17/22

Income Statement

MetricCLGNIndustry medianRank
Total Revenue $3M $110M 16/19
Operating Income -$29M -$6M 21/25
R&D Expense $19M $20M 12/22
Cost of Goods Sold $2M $55M 17/22

Dividend & Shareholder Information

MetricCLGNIndustry medianRank
Shares Outstanding 2M – –

Balance Sheet Highlights (USD millions)

Total Current Assets$7M62.7% of assets
Cash & Short-term Investments$6M51.9% of assets
Accounts Receivable$0.00M0.0% of assets
Inventory$570K5.3% of assets
Total Liabilities$5M43.7% of assets
Quarterly Financial Reports

CLGN quarterly financials and insider trading

Industry Peers · Orthopedic, Prosthetic & Surgical Appliances & Supplies

Collplant Biotechnologies Ltd (CLGN) industry peers

Companies classified under the same SEC industry code as Collplant Biotechnologies Ltd (Orthopedic, Prosthetic & Surgical Appliances & Supplies): 27 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.

Reveal all forecasts · See exact % predictions for all competitors

Sign up free
Company 90-Day AI Forecast (Alpha) Market Cap P/E Ratio P/B Ratio
CLGN Collplant Biotechnologies Ltd ▶ $7M – 1.1x
ISRG Intuitive Surgical Inc ▼ $150.74B 49.0x 8.3x
STE Steris Plc ▼ $21.71B 28.8x 3.0x
ZBH Zimmer Biomet Holdings, Inc. ▼ $18.12B 18.9x 1.4x
SNN Smith & Nephew Plc ▼ $12.75B 16.7x –
ALGN Align Technology Inc ▶ $10.46B 25.7x 2.5x
MSA Msa Safety Inc ▼ $6.91B 22.2x 4.9x
ESTA Establishment Labs Holdings Inc. ▲ $1.76B – 81.6x
ENOV Enovis Corp ▶ $1.13B – 0.8x
CDRE Cadre Holdings, Inc. ▼ $1.13B 26.9x 3.3x
AVR Anteris Technologies Global Corp. ▶ $590M – 2.4x
SMTI Sanara Medtech Inc. ▼ $305M – 38.4x
INGN Inogen Inc ▲ $166M – 1.0x
LAKE Lakeland Industries Inc ▲ $90M – 0.7x
NTRB Nutriband Inc. ▲ $76M – 14.2x
APT Alpha Pro Tech Ltd ▲ $57M 14.2x 0.9x
COCH Envoy Medical, Inc. ▼ $52M – –
MYO Myomo, Inc. ▲ $48M – 8.2x
MLSS Milestone Scientific Inc. ▲ $29M – 8.4x
LFWD Lifeward Ltd. ▲ $17M – 1.4x
UEEC United Health Products, Inc. ▲ $14M 5.2x –
CUPR Cuprina Holdings (Cayman) Ltd ▶ $13M – –
RGNT Regentis Biomaterials Ltd. ▶ $10M – 2.2x
LGMK Logicmark, Inc. ▲ $1M – 0.1x
BBLG Bone Biologics Corp ▲ $1M – 0.3x
RBOT Vicarious Surgical Inc. ▼ $550K – 0.1x
FEED Envue Medical, Inc. ▼ $340K – –

Where CLGN sits on the market map

Industrial Applications and Services · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Explore the map →
News

Collplant Biotechnologies Ltd (CLGN) stock news

Loading...

FAQ

Collplant Biotechnologies Ltd (CLGN) stock forecast FAQ

What is the Collplant Biotechnologies Ltd (CLGN) stock forecast?

On Oct. 16, 2026, CLGN is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5172 stocks scored that day.

How accurate are Collplant Biotechnologies Ltd stock predictions?

For CLGN, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -14.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -17.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

How often are Collplant Biotechnologies Ltd forecasts updated?

Collplant Biotechnologies Ltd forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.

Which companies are Collplant Biotechnologies Ltd's industry peers?

27 issuers in our coverage, CLGN included, share the SEC industry code Orthopedic, Prosthetic & Surgical Appliances & Supplies. The largest are: Intuitive Surgical Inc (ISRG), Steris Plc (STE), Zimmer Biomet Holdings, Inc. (ZBH), Smith & Nephew Plc (SNN), Align Technology Inc (ALGN), Msa Safety Inc (MSA).

This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.